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Abstract
Background: Concerns have been expressed that inhaled nanoparticles may behave differently to larger particles in
terms of lung clearance and translocation, with potential implications for their toxicity. Studies undertaken to
investigate this have typically involved limited post-exposure periods. There is a shortage of information on longer-
term clearance and translocation patterns and their dependence on particle size, which this study aimed to address.
Methods: Rats were exposed (<3 h) nose-only to aerosols of spark-generated radioactive iridium-192 nanoparticles of
four sizes: 10 nm, 15 nm, 35 nm and 75 nm (count median diameter) (aerosol mass concentrations 17, 140, 430, and
690 μg/m3, respectively). The content of iridium-192 in the whole animal, organs, tissues, and excreta was measured at
various times post-exposure to≥ 1 month. Limited toxicological investigations were undertaken for the 10 nm aerosol
using bronchoalveolar lavage fluid. Elemental maps of tissue samples were produced using laser ablation inductively
coupled plasma mass spectrometry and synchrotron micro-focus x-ray fluorescence. The chemical speciation of the
iridium was explored using synchrotron micro focus x-ray near-edge absorption spectroscopy.
Results: Long-term lung retention half-times of several hundred days were found, which were not dependent on particle
size. There was significant variation between individual animals. Analysis of bronchoalveolar lavage fluid for the 10 nm
aerosol indicated a limited inflammatory response resolving within the first 7 days. Low levels of, particle size dependent,
translocation to the kidney and liver were found (maximum 0.4% of the lung content). Any translocation to the brain was
below the limits of detection (i.e. < 0.01% of the lung content). The kidney content increased to approximately 30 days
and then remained broadly constant or decreased, whereas the content in the liver increased throughout the study.
Laser ablation inductively coupled plasma mass spectrometry analysis indicated homogeneous iridium distribution in the
liver and within the cortex in the kidney.
Conclusions: Slow lung clearance and a pattern of temporally increasing concentrations in key secondary target organs
has been demonstrated for inhaled iridium aerosol particles < 100 nm, which may have implications for long-term
toxicity, especially in the context of chronic exposures.
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Background
Rapid developments in the field of nanotechnology over
the past decades, which have led to the production of an
expanding range of nanomaterials being used in an in-
creasing number of products, have been paralleled by
growing concerns about the potential health effects of
exposures to these materials. One such concern is that
inhaled nanoparticles may behave differently to larger
particles in terms of their clearance from the lung and
translocation to secondary target organs and tissues,
with concomitant implications for potential toxicity.
This is a particular concern in relation to poorly soluble
materials due to their potential biopersistence. A num-
ber of studies have investigated these issues and there
appears a growing consensus that translocation is low,
typically < 1% of lung deposition to key organs, for highly
insoluble nanomaterials [1]. The majority of studies
have, however, only considered limited post-exposure
timescales. Furthermore, the situation in relation to lung
clearance is unclear, with many studies indicating clear-
ance timescales of the same order as larger particles (e.g.
[2]) but a minority suggesting much slower clearance
(e.g. [3, 4]). In both areas there is a lack of studies
systematically investigating the effect of particle size.
The majority of studies have been undertaken using
micron-sized aerosols of agglomerated nanoparticles,
which, whilst clearly relevant to some occupational ex-
posure situations, are potentially less so for exposures of
members of the public resulting from the use of prod-
ucts containing nanoparticles, as studies of consumer
spray products have indicated the potential for expo-
sures to nano-sized aerosols [5, 6]. In general there is a
lack of information on long-term clearance and trans-
location patterns for such aerosols.
The potential toxic effects of inhaled nanoparticles on
the lung and other organs and tissues depend on a num-
ber of factors, including: amount (dose); location (e.g.
sub-organ/tissue structure, cell type, subcellular); and
chemical state, in particular whether the material re-
mains in its original nano-particulate form or is in an
alternative form(s) as a result of dissolution and subse-
quent chemical reactions in vivo. Information on these
factors is therefore an important input to an assessment of
toxic potential.
The primary objective of this study was to investigate
the effect of aerosol particle size on the long-term clear-
ance and translocation of nanoparticles following inhal-
ation. A secondary aim was to explore the localisation
and chemical state of the inhaled material. Rats were ex-
posed in a nose-only inhalation system to radioactive
iridium-192 aerosols of four sizes, chosen to cover the
majority of the nano-size range (nominal sizes: 10, 15,
35, and 75 nm), and the content of iridium-192 in the
whole animal, a number of organs and tissues, and
excreta was measured at various times post-exposure.
Toxicological investigations were also undertaken for
the 10 nm aerosol using bronchoalveolar lavage fluid
(BALF). A number of techniques were used to investi-
gate the localisation and chemical speciation of the in-
haled iridium, using samples from the iridium-192
inhalation experiments and additional inhalation experi-
ments using non-radioactive iridium aerosols (10 nm and
75 nm). Tissue samples were imaged using transmission
electron microscopy and elemental maps produced using
both laser ablation inductively coupled plasma mass
spectrometry (LA-ICP-MS) and synchrotron micro focus
x-ray fluorescence (μ-XRF). In addition, synchrotron
micro focus X-ray near-edge absorption spectroscopy
(μ-XANES) was used to explore iridium speciation.
Iridium nanoparticles are currently found in only a
limited number of consumer products, although poten-
tial uses being investigated, including catalysts (e.g. [7]),
could lead to more widespread exposures. However, the
objective of this study was not to investigate iridium per
se but, as has been the case in other studies [8], iridium
nanoparticles were chosen as a model poorly soluble
particle (in bulk it is one of the most corrosion resistant
and insoluble elements), with the aim that the study




The characteristics of the iridium-192 aerosols for the
main study are given in Table 1 with average particle size
distributions in Fig. 1. Representative transmission elec-
tron microscopy (TEM) images of aerosol particles col-
lected during exposures show that the spark generated
aerosols consist of chain agglomerates (Additional file 1:
Figure S1). Primary particle size was consistent across all
agglomerate sizes investigated with diameters in the
range 1.2 nm to 2.9 nm. The 15 nm iridium-192 aerosol
used for the supplementary study was similar to that
used for the main study, with a count median diameter
(CMD) of 16.6 ± 0.1 nm (Additional file 1: Table S1).
The characteristics of the non-radioactive iridium aero-
sols were also similar to those used in the main study
(Additional file 1: Table S2).
Radionuclide content of biological samples
The iridium-192 content of organs, tissues, blood
samples and excreta at various times post-exposure are
contained in Additional file 2. Results for a number of
organs and tissues have been used to derive size-
dependent deposition efficiencies in the respiratory tract
and its component parts (head airways, total lung,
tracheobronchial region and alveolar region) and these
have been reported previously [9].
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Lung clearance
The iridium-192 content of the lung, gastrointestinal
tract (GIT) and pelt and also the total in and on the rat
measured during the first two weeks post-exposure
(Additional file 1: Figure S2), indicates that initially for
the 10 nm aerosol the iridium-192 in the lung is similar
to that in the GIT and pelt, however, for both the 15 nm
and 35 nm aerosols the pelt and GIT contents are simi-
lar but approximately a factor of between 2 and 5 times
lower than the lung content. For the 75 nm aerosol at
the first time point the lung content is also approxi-
mately double that of the pelt and GIT, which are similar
(Additional file 2). The pelt and GIT content reduce sig-
nificantly during this time period so that by the end of
the first few days the lung content accounts for more
than 97% of the total.
The whole-body iridium-192 content for all particle
sizes shows an initial fast clearance phase during the first
few days, reflecting both clearance from the pelt and
from the head and ciliated airways, followed by a much
slower clearance phase with a half-time of between ap-
proximately 100 and 500 days (Fig. 2). The iridium-192
content of the lung measured at various times post-
exposure (Additional file 1: Figure S3) also indicates
slow clearance from the lung suggesting half-times in
excess of 100 days for all particle sizes. The average
whole-body iridium-192 content from the supplemen-
tary study with the 15 nm aerosol for four different
exposure durations (and thus deposited doses) shows a
similar pattern of slow clearance for all four groups,
consistent with that seen in the main study (Additional
file 1: Figure S4). Interestingly, the results for individual
animals (Fig. 3) indicate an animal specific variation in
clearance patterns which becomes more pronounced
with increasing exposure duration.
Bronchoalveolar lavage fluid
Bronchoalveolar lavage was performed on animals ex-
posed to the 10 nm (days 0, 3, 7, 30 and 90 post-
exposure) and 35 nm (days 3 and 28 post-exposure)
aerosols. The fraction of the iridium-192 in the lung
removed by lavage showed little variation with time
following exposure (average 35%) - at day 0 the majority
was associated with the supernatant, however, at later
Table 1 Aerosol characteristics for main iridium-192 study






10 9.8 ± 0.1 1.37 ± 0.01 2.85 ± 0.10 490 ± 90 0.17 ± 0.03
15 15.6 ± 0.3 1.67 ± 0.01 9.09 ± 0.14 2380 ± 250 1.39 ± 0.15
35 33.4 ± 2.1 1.69 ± 0.02 5.63 ± 0.13 590 ± 140 4.28 ± 0.84
75 76.3 ± 1.9 1.62 ± 0.01 1.10 ± 0.03 600 ± 100 6.92 ± 1.38
Aerosol particle size distribution expressed as count median diameter (CMD) and geometric standard deviation (GSD). Values presented as mean ± standard deviation.
Concentrations for the 10 nm aerosol have been corrected for system losses (see Methods for details)
Fig. 1 Average mobility equivalent size distributions of iridium-192 aerosols. Error bars shown are the standard deviation
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Fig. 2 Average whole-body iridium-192 content for 10 nm, 15 nm, 35 nm, and 75 nm aerosols: (a) normalised to whole body content at 0 h and
(b) normalised to whole body content at 8 d, with theoretical plots for retention half-times of 100 days (dotted line) and 500 days (dashed line)
Fig. 3 Whole-body iridium-192 content of individual animals normalised to whole-body content at 0 h for: (a) 10 min, (b) 20 min, (c) 40 min, and
(d) 60 min exposures to 15 nm iridium-192 aerosol
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times the majority (>80%) was associated with the
cellular fraction (Additional file 1: Table S3).
Excretion
The excretion of iridium-192 (Additional file 1: Figure S5)
is predominantly via faeces, with a rapid reduction within
the first week consistent with an initial fast clearance
from the head airways, ciliated airways and pelt (via
grooming). Urinary excretion levels are lower and
show a less significant reduction with time. Expressed
as a function of the initial lung deposit, levels are similar
for the 10 and 15 nm aerosols but significantly lower for
the larger aerosol particles.
Translocation
The iridium-192 in the liver and kidneys as a function of
the lung content are presented in Fig. 4. The absolute
levels of translocation are low (<1%). For kidney the peak
is approximately 0.35% and for liver 0.20%. For both
organs translocation is higher for smaller particle sizes,
with the results for 35 nm and 75 nm aerosols very simi-
lar. The temporal trend for liver is a constant increase
over the time period investigated (max 110 days), whereas
that for kidney indicates a peak at around 30 days
followed by a levelling off or reduction. The iridium-192
levels in the brain were <minimum detectable activity
(MDA) for all particle sizes. Iridium-192 in spleen and
blood samples was <MDA for the two larger particle sizes;
for the others some samples were >MDA but with no
clear pattern. The iridium-192 content of the carcass was
typically 0.1 to 0.6% of the lung level, with no clear pattern
with respect to particle size or time post-exposure.
Cytotoxicity
Analysis of BALF from animals exposed to the 10 nm
aerosol and sacrificed at days 3 and 7 post-exposure
indicated limited toxicity. There was a small increase
in the neutrophil population at day 3 (2.4 ± 0.7%)
compared with control group, which recovered by day
7 (Additional file 1: Figure S6). There was no significant
change in total cell numbers (4.1 ± 0.4 × 106) or numbers
of macrophages or lymphocytes. Only at day 0 was there a
significant increase in lactate dehydrogenase (LDH) which
recovered by day 3 (Additional file 1: Figure S6).
Electron microscopy
Electron microscopy images and associated elemental
analysis of BALF cell samples from the 75 nm aerosol ex-
posed animals at 1, 5 and 30 d post-exposure clearly indi-
cate the presence of iridium nanoparticles within BALF
cells (Additional file 1: Figures S7, S8). Dense nano-sized
particles of similar morphology to the aerosolised particles
were also seen in other samples (particle sizes 10 nm (lung
and BALF cells) and 75 nm (lung); 1, 5, and 30 d post-
exposure (data not shown)), however, it was not possible
to confirm that these were iridium as elemental analysis of
particles in samples was not undertaken for these samples.
Laser ablation ICP-MS
Elemental maps of iridium (and other elements for com-
parison purposes) were produced for sections of lung,
liver, kidney, and brain, and BALF cells. Iridium is clearly
seen in the lung at 1, 5 and 30 days post-exposure for
both the 10 nm and 75 nm aerosol (Additional file 1:
Figures S9, S10). Elemental maps of BALF cells samples
for the 10 nm aerosol at 3 days post-exposure and
35 nm aerosol at 589 days post-exposure show similar
patterns of iridium association with BALF cells (Fig. 5).
At 30 days post-exposure iridium is clearly seen in the
kidney (Fig. 6) and liver (Additional file 1: Figure S11)
for both the 10 nm and 75 nm aerosols. The iridium is
concentrated in the kidney cortex. Further investigation
of a small area of cortex using a reduced spot size failed
to establish whether the iridium was associated with
particular structures. The results for the liver indicate a
homogenous spread, however, at this resolution it is not
Fig. 4 Iridium-192 content of (a) liver and (b) kidney normalised to contemporaneous lung content for 10 nm, 15 nm, 35 nm, and 75 nm
iridium-192 aerosols
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possible to identify whether the iridium is associated
with specific organ structures.
Synchrotron X-ray spectroscopy
Elemental maps (μ-XRF) were produced for one lung
section (10 nm, 1 day post-exposure (Additional file 1:
Figure S12)) and two BALF cell samples (10 nm, 3 days
post exposure (Additional file 1: Figure S12) and 35 nm,
589 days post-exposure (Fig. 7)), which identified areas
containing iridium from which μ-XANES spectra were
collected. The μ-XANES spectra are difficult to inter-
pret. Those for the lung section and the 589 day BALF
cell sample are very similar (Fig. 8), which could suggest
limited change in particle state following exposure,
however, those for the standards are also very similar
(Additional file 1: Figure S13). Additional studies are
required to produce: (a) additional sample spectra, and
(b) spectra from standards of compatible form, such that
detailed fitting programs can be used to compare sample
spectra to standards.
Discussion
This study investigated the effect of inhaled aerosol
particle size (range 10–75 nm) on lung clearance and
translocation to other organs and tissues.
Relevance of aerosol mass concentrations
The aerosol mass concentrations used in this study
(range 0.2 to 6.9 mg/m3) are typically higher than those
suggested by limited measurements of consumer spray
products (e.g. 17 μg/m3 nano-fraction [5]). The masses
deposited in the lung (in the μg range) are two orders of
magnitude greater than available estimates of deposited
doses per product use [5, 10], and thus broadly consist-
ent with the mass deposited in the lung by daily use of a
product for 3 or 4 months. However, it must be recog-
nised that the actual lung burden after this time would
differ as a result of clearance over this period.
Lung clearance
Assessment of the content of organs and tissues indi-
cated that after the first few days post-exposure the
majority of the iridium-192 (>97%) was retained in the
lung, thus measurements of the whole-body content
were representative of those in the lung. These show
slow long-term clearance of iridium from the rat lung
(i.e. retention half-times of several hundred days) with
no dependence on particle size within the range consid-
ered (Fig. 2). For the 15 nm aerosol there was no dose
dependent effect on clearance over the range of
deposited dose used (0.5–3.2 μg/animal – Additional file 1:
Table S4). The variation in clearance rates between individ-
ual animals exposed to the 15 nm aerosol for 10, 20, 40 and
60 mins, tended to increase with exposure duration (ap-
proximate range 200–500 days retention half-time)
(Fig. 3).The results may reflect the effect of changes in
factors such as animal position, behaviour and breath-
ing patterns with time and/or inherent variability within
the population.
Reported lung retention half-times following the inhal-
ation of low concentrations of low solubility nanoparti-
cles (e.g. TiO2, Carbon Black, CeO2) in rats are typically
in the range 40–60 days (e.g. [11–13]), i.e. comparable
to those for larger particles and significantly shorter than
Fig. 5 Laser ablation inductively coupled plasma mass spectrometry (LA-ICM-PS) generated elemental maps of BALF cell samples from rats at 3 days
post-exposure to 10 nm iridium aerosol (A) and 589 days post-exposure to 35 nm iridium-192 aerosol (B); showing light microscopy image of the cell
sample analysed (a) and the distribution of iridium (b). Scales are in counts per second. Some areas have been highlighted to aid comparison
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found in this study. Slower clearance rates have been re-
ported for such materials but typically only at high aero-
sol concentrations and have been interpreted as
indicating ‘lung overload’ associated depression of alveo-
lar macrophage clearance [11–13]. The majority of such
studies have, however, been undertaken using aerosols
with agglomerated particles in the micron-size range.
There are few studies which have directly addressed the
clearance of inhaled nano-sized aerosol particles. Two
studies using silver nanoparticle aerosols (15–17 nm) indi-
cated rapid clearance [14, 15] and studies using a gold
nanoparticle aerosol (16 nm) and a C60 (fullerene) aerosol
(55 nm) estimated lung retention half-times of, respect-
ively, 30 days [16] and 26 days [17]. In all these studies,
however, clearance was only considered to 7 days post-
exposure, so there is a measure of uncertainty surrounding
the extrapolation of these estimates to long-term clear-
ance, especially given the dominance of fast mucociliary
clearance during the initial days post-exposure. One study
investigated the clearance of gold nanoparticles to 28 days
post-exposure [4]. Male Sprague-Dawley rats were ex-
posed in a nose-only system to aerosols produced by
atomizing 1% citrate dispersions containing small (13 nm)
or large (105 nm) gold particles. The aerosol particles pro-
duced were predominantly in the nano-size range for both
materials, however, the size of the aerosolised gold parti-
cles is unclear as the system produced a large number of
citrate aerosol particles, which makes interpretation of the
particle size distribution data difficult. The study estimated
a retention half-time of 180 days for the larger primary
particles, which is comparable with that found in this
study, although with only 3 data points there is clearly
Fig. 6 Laser ablation inductively coupled plasma mass spectrometry (LA-ICM-PS) generated elemental maps of kidney samples at 30 days post-exposure
from rats exposed to 10 nm (A) and 75 nm (B) iridium aerosols; showing light microscopy image of the kidney section analysed (a) and the distribution
of copper (a), iridium (b) and an overlay of the two plots (c) (copper, magenta; iridium, green; both, white) Scales are in counts per second. The copper
distribution map is included to enhance visualisation of the localisation of the iridium; results from control animals (not shown) indicate no iridium is
present and the same overall pattern of copper distribution
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significant uncertainty surrounding this estimate. A reten-
tion half-time for the smaller particles of 44 days was also
estimated, although there is significant uncertainty sur-
rounding this as the concentration of gold in the lung for
the 3 d and 28 d groups was higher than for the 1 d group.
One of the few inhalation studies to investigate longer-
term clearance of nano-sized aerosols also used iridium-
192 particles produced by spark generation [2]. Aerosols
of two sizes, 15 nm and 80 nm, were delivered by endo-
tracheal tube to male Wistar rats for between 1 and
1.5 h (reported lung burdens 2 to 4 μg/rat [8]). The
whole-body and various organ iridium-192 contents
were measured at intervals up to 6 months post-
exposure. Using the whole-body measurements from day
3 post-exposure a retention half-time of approximately
100 days was estimated, broadly in line with clearance
for larger particle sizes and markedly lower than that
seen in this study. It is not immediately clear why two
very similar studies should produce different clearance
rates. The sex of the animals used was different, but
whilst there has been some suggestion of a sex difference
in translocation [18, 19] there is no indication of such
for lung clearance. The main difference between the
studies is the exposure route. Endotracheal intubation
results in the delivery of the whole aerosol directly to
the lung, by comparison, initial delivery to the nose
means that the aerosol ‘seen’ by the lung is modified as a
result of deposition within the nasal cavities with fewer
of the smaller particles present (45% of particles < 6 nm
- Additional file 1: Figure S14). This could modify initial
clearance rates, as there are indications that particles <
6 nm can enter the blood stream quickly [20], but it is
unclear how this could affect long-term clearance rates.
The results of the two studies also differed with respect
to the lavageable fraction: in our study approximately 30
to 40% of the iridium-192 within the lung could be re-
moved by bronchoalveolar lavage at all time points con-
sidered, whereas in the earlier study the lavageable
fraction (46% at 0 h) decreased markedly during the first
6 h to 19% and further to 6% at 21 days and thereafter
(to 6 months) remained fairly constant at this level [21].
Translocation and excretion
The results of this study indicate low levels of transloca-
tion of iridium from the lung to the kidney and liver
(maximum 0.4% of lung burden) with translocation to
kidney higher than liver. Translocation decreased as
Fig. 7 Elemental μ-XRF map of BALF cell sample from animal exposed
to 35 nm iridium aerosol at 589 d post-exposure, obtained using the
I18 beamline at the Diamond Light Source (pixel size 4 μm × 4 μm);
showing light microscopy image of the BALF cell sample analysed (a)
and the distribution of iridium (blue) (b). Some areas have been
highlighted to aid comparison
Fig. 8 Iridium L(III)-edge μ-XANES spectra derived from iridium-rich pixels from samples of BALF cells shown in Fig. 7 and lung tissue at 1 day
post-exposure to 10 nm iridium aerosol. The lung spectrum is the sum over 6 pixels and that for the BALF over 10 pixels
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particle size increased but was similar for the two larger
sizes. The temporal trend for liver is a constant increase,
whereas that for kidney indicates a peak at around
30 days with a levelling off or reduction after this time.
Levels of activity in the brain were below the limits of
detection (i.e. < 0.01% of the activity in the lung) and
patterns for blood and spleen were unclear.
These low levels of translocation are consistent with the
results of a recent review which concluded that nanoparti-
cle translocation to secondary target organs following in-
halation is typically < 1% of lung deposition for insoluble
nanomaterials [1]. However, the majority of the studies
reviewed only considered limited post-exposure timescales
and used micron-sized agglomerated aerosol particles.
There are very few studies of the translocation of inhaled
nano-sized aerosol particles and the results, although con-
firming overall low translocation levels, show significant
variation. For example, one study using an aerosol of gold
nanoparticles (<5 nm) and Sprague-Dawley rats found
translocation only to the kidney with higher values for fe-
male than male [19], whereas a further study from the
same group using aerosols produced by atomizing 1% cit-
rate suspensions containing small (13 nm) or large
(105 nm) gold nanoparticles found gold levels above con-
trol for the lung, spleen, liver and brain for the small aero-
sol only at day 1, with only the lung and spleen levels
significant at day 28; there was no significant increase in
kidney levels [4]. Another study exposed male Wistar rats
to aerosols of gold nanoparticles of two primary particle
sizes, 7 nm and 20 nm, but with similar aerosol particle
agglomerate sizes, respectively 46 and 42 nm [22]. The re-
sults for kidneys and liver indicated translocation in the
range 0.1–0.4%, similar to that found in this study; how-
ever, they also found translocation to a wide range of other
organs and tissues including parts of the brain. A study
using iridium-192 nanoparticle aerosols found transloca-
tion to secondary organs was lower for the 80 nm aerosol
than the 15 nm aerosol [8], which is consistent with the
size dependent pattern found in this study, however, the
degree of translocation was higher at 7 days by approxi-
mately an order of magnitude than that found in this
study. The temporal pattern, i.e. low levels of translocation
to liver, spleen, brain and kidneys at 3 weeks, reducing
thereafter [2], also differs from that found in the
current study. As indicated above, it is not clear why
such similar studies would produce different results.
The increased percentage of smaller particles present
for the endotracheal delivery may have increased the
initial translocation, but, as indicated earlier, the dif-
ference in mass terms is small. The use of animals of
a different sex may have had an influence, a number
of studies have indicated sex differences in transloca-
tion to kidneys [18, 19], but neither of these factors
can fully explain the differences.
There are few studies that have investigated excretion
following the inhalation of nano-sized aerosols. We
found iridium excretion is predominantly via faeces,
consistent with other studies [2, 22], for which there was
no evidence of a size dependent effect. In line with the
translocation results, there was a suggestion of a size-
dependent effect for urinary excretion, with this being
greater for the two smaller particle sizes. A study to in-
vestigate the renal filtration threshold for metal based
nanoparticles used quantum dots of 6 sizes (hydro-
dynamic diameter 4.4 to 8.7 nm) administered intrave-
neously and found that only particles < 5.5 nm were
excreted [23]. The aerosol particle size distributions all
have some fraction < 5.5 nm, with the proportion de-
creasing as the average particle size increases. Thus the
results may reflect the excretion of this small particle
fraction, however, the iridium in urine may have been in
ionic rather than particulate form.
Localisation and speciation
A secondary objective of this series of experiments was
to explore the use of a number of techniques to explore
localisation and chemical speciation. TEM identified
iridium particles within BALF cells and lung tissue. LA-
ICP-MS analysis of lung and BALF cell samples clearly
indicated the presence of iridium. At low resolution the
distribution of iridium was homogenously distributed
throughout the lung. At higher resolution the iridium is
clearly seen at short times post-exposure associated with
the epithelial surface. BALF cell samples indicate the
presence of iridium in cells, at short and long times
post-exposure (Fig. 5). The μ-XRF elemental maps of
lung tissue and BALF cells showed a similar pattern.
The μ-XANES analysis of μ-XRF iridium ‘hot spots’ in a
lung sample at 1 day post-exposure and a BALF sample
at 598 days post-exposure show little change in the
chemical speciation suggesting limited if any dissolution.
However, systematic analysis of further samples is neces-
sary to confirm these findings. The LA-ICP-MS analysis
indicates the presence of iridium in the liver and kidney
(Fig. 6), no iridium was seen in the brain (results not
shown). For liver the iridium was homogeneously dis-
tributed, whilst that for the kidney showed concentration
in the cortex. The intention is to further investigate the
use of μ-XANES to explore speciation in these tissues.
Implications for toxicity
Limited toxicological investigations (10 nm aerosol only)
were carried out as part of this study. These indicated
that inflammation within the lung shortly after exposure
was low, resolving within a week, consistent with find-
ings from a similar study using iridium-192 aerosols
[21]. However, slow clearance from the lung suggests the
potential for accumulation within the lung following
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chronic exposure, which requires further investigation.
Although the quantities of material translocated to the
liver and kidney are small, if this pattern were repeated
for long-term exposures then levels could increase sig-
nificantly, and this possibility also requires further inves-
tigation. The potential toxicological implications of any
long-term build-up of concentrations within the lung
and other organs are unclear and would require further
investigation. The findings of a recent review [24] sug-
gest that there is currently no convincing evidence for
systemic toxicity following exposure to low solubility
nanomaterials, however, they indicate that it is currently
an open question whether long-term low dose accumu-
lation could lead to material levels high enough to pro-
duce any systemic effects.
Conclusions
This study found long-term lung retention half-times for
iridium of several hundred days following exposure to
nano-sized aerosols of iridium, which were not
dependent on particle size in the range considered
(10 nm to 75 nm). Analysis of BALF for the 10 nm aero-
sol indicated a limited inflammatory response resolving
within the first 7 days. Low levels of, particle size
dependent, translocation (maximum 0.4% of the lung
burden) of iridium to the kidney and liver were found.
Any translocation to the brain was below the limits of
detection (i.e. < 0.01% of lung burden). The kidney con-
tent increased to approximately 30 days and then
remained broadly constant or decreased, whereas the
content in the liver increased throughout the study. LA-
ICP-MS analysis indicated homogeneous iridium distri-
bution in the liver and within the cortex in the kidney.
If the pattern of slow lung clearance and temporally
increasing concentrations in key secondary target organs
were repeated for long-term exposures then levels could
increase significantly, and this possibility requires further
investigation. The potential toxicological implications of
any such accumulation would also need investigation.
Understanding the clearance and translocation processes
for the inhaled iridium nanoparticles requires more in-
formation on the localisation and chemical speciation of
the iridium, in particular to understand whether particle
dissolution is significant – to help address, for example,
possible hypotheses such as that slow lung clearance is a
result of dissolution followed by iridium binding to spe-
cific proteins. Initial investigations reported here have
provided some relevant information but further studies
are required.
Iridium was chosen for this study as a model poorly
soluble material, as in bulk it is one of the most corro-
sion resistant and insoluble elements. However, the
clearance results obtained differ from those for some
other poorly soluble nanomaterials (albeit typically
obtained using micron sized agglomerate aerosols),
therefore caution must be exercised in extrapolating
from these results for iridium to other materials. Add-
itional studies using other materials are required to fur-
ther explore the biokinetics of inhaled nano-sized
aerosols of poorly soluble materials.
Methods
Experimental design
Details of the experimental plan for the main and sup-
plementary studies are presented in Table 2. For the
main study the intention was for the exposure duration
to be the same (1 h) for all aerosols, however, the re-
quirement to deliver a measureable quantity of radio-
nuclide, and limitations imposed due to radioactive
decay of the iridium-192 electrodes resulted in longer
exposure durations for most of the groups.
Nanoparticle aerosol production and exposure system
A schematic diagram of the nose-only inhalation expos-
ure system is shown in Fig. 9. Aerosols of nano-sized
iridium particles were generated using a spark generator
(DNP 4000, Palas, Karlsruhe, Germany) with iridium
wire electrodes held in custom made electrode holders.
The sparking frequency used was between 90 Hz and
300 Hz and, if necessary, was adjusted during exposures
to maiantain a constant aerosol size. Argon (Zero Grade
Argon 99.999% minimum purity, BOC Industrial Gases,
Guildford, UK) was filtered and delivered to the spark
generator at a constant flow rate controlled by an argon
calibrated mass flow controller (MKS, 1179A Mass-Flo®,
Andover, MA, USA). The aerosol from the generator
passed into a stainless steel neutralising and mixing
chamber, containing a krypton-85 source (NER8180 cap-
sule, 740 MBq (26/10/2009), Eckert & Ziegler Isotope
Products GmbH, Berlin, Germany), where it was mixed
with oxygen and nitrogen. Oxygen and nitrogen
(99.999% minimum purity, BOC Industrial Gases, Guild-
ford, UK) were filtered and the flow controlled using cal-
ibrated mass flow controllers (MKS, 1179A Mass-Flo®,
Andover, MA, USA). Before mixing the oxygen and ni-
trogen were humidified using a Nafion® gas dryer (Perma
Pure PD-Series™, Toms River, NJ, USA) to achieve a rela-
tive humidity after mixing with the aerosol of at least
30%. To achieve the largest agglomerate particle size
additional aerosol aging was required and a 3.8 L stain-
less steel aging chamber, with an aerosol residence time
of about 45 s, was introduced after the neutralising and
mixing chamber.
The resulting aerosol entered a custom built nose-only
exposure manifold (EMMS, Bordon, UK) [9]. This com-
prises four nose-only exposure chambers, each with 9
ports for animals or sampling probes. Depending on the
number of animals to be exposed, between 1 and 4
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chambers can be used, with those not in use isolated
from the system. The rats are held in restraining tubes
attached to the ports. The aerosol exhaust is filtered and
the exposure manifold is inside a glove box held at a
negative pressure of −3 in. H2O to provide secondary
containment of the aerosol. Flow rates to the manifold
were set to ensure delivery of at least 2 to 3 times the re-
spiratory minute volume of the exposed animals (i.e. at
least 0.5 L/min per exposure port) [25]. The oxygen con-
centration, temperature and relative humidity of the gas
delivered to the exposure chamber were continuously
measured during exposures using a MX300 medical oxy-
gen analyser (Teledyne Analytical Instruments, City of
Industry, CA, USA) and a HMT333 temperature/relative
humidity sensor (Vaisala, Boulder, CA, USA). Across all
experiments, the delivered gas temperature, relative
humidity and oxygen concentration ranged between 19.0
and 23.5 °C, 30–55%, and 21.0–21.5%, respectively.
Nanoparticle aerosol characterisation
For the main experiments using radioactive iridium,
aerosol activity concentrations were determined using
Pallflex® emfab™ filters (Pall Life Sciences, Ann Arbor,
MI, USA) held in a 47 mm anodized aluminium filter
holder (Pall Life Sciences, Ann Arbor, MI, USA). The
aerosol was drawn through the filter at between 0.2 and
1.2 Lmin−1 for between 30 s and 2 mins, depending
upon the electrode specific activity and aerosol mass
concentration. Mass concentrations were derived from
the activity concentrations using the specific activity of
the electrodes. For the experiments using non-
radioactive iridium electrodes, the average aerosol mass
concentration was determined gravimetrically using the














10* 120 36 0 h (6), 24 h (4), 3d (4),
7d (4), 14d (4), 30d (5),
63d (4), 90d (5)
15 75 35 0 h (10), 24 h (5), 2d (4),
5d (4), 9d (4), 28d (4),
109d (4)
35 180 36 0 h (6), 24 h (6), 3d (4),
7d (4), 14d (4), 28d (4),
64d (4), 589d (4)
75 60 9 0 h (5), 30d (4)
Supplementary






study B – Additional
samples for imaging
10 120 6 24 h (2), 5d (2), 30d (2)
75 60 6 24 h (2), 5d (2), 30d (2)
*For the 10 nm study additional animals (system controls) were exposed in
the same system to gases without nanoparticles for 120 mins and sacrificed at
3 and 7 days post-exposure
Fig. 9 Schematic of exposure system (note that aging chamber was used for 75 nm aerosols only, for non-radioactive iridium aerosols the SMPS
and NAS sampled directly from a chamber port, and TEOMTM malfunctioned for 15 nm aerosol)
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same filter sampling method but the aerosol was drawn
through the filter for the duration of the experiments at
sampling flowrates of 1 Lmin−1 and 0.25 Lmin−1 for the
10 nm and 75 nm experiments respectively. A TEOM™
ambient particulate monitor (Model 1400a, Thermo Sci-
entific, Franklin, MA, USA) was used to continuously
monitor the aerosol mass concentration delivered to the
exposure manifold at a sampling flowrate between 0.5
and 1 Lmin−1 for all aerosols except the 15 nm, when it
malfunctioned. The number concentration and particle
size distribution of the aerosol delivered to the exposure
manifold were also continuously measured during expo-
sures using a condensation particle counter (CPC model
3775, TSI Inc., Shoreview, MN, USA) and a scanning
mobility particle sizer (SMPS model 3936 N76, TSI Inc.,
Shoreview, MN, USA) with a differential mobility ana-
lyser (DMA) (model 3081, TSI Inc., Shoreview, MN,
USA) for the 75 nm aerosol and a nano-DMA (N-DMA
model 3085, TSI Inc., Shoreview, MN, USA) for the
others. The morphology of the aerosol particles deliv-
ered to the manifold was determined with high reso-
lution transmission electron microscopy (TEM) (JEOL
3000 F, JEOL Inc., Tokyo, Japan). Samples for TEM were
taken directly onto 400 mesh copper TEM grids with
lacey carbon film using an electrostatic precipitator (TSI
3089 nanometer aerosol sampler (NAS), TSI Inc., Shore-
view, MN, USA). Sampling took place throughout the
exposure for the 10 nm and 15 nm aerosols and at a
number of times during the 35 nm and 75 nm exposures
for a few minutes on each occasion.
Using the standard experimental configuration de-
scribed above, the aerosol delivered to the manifold was
continuously monitored during exposures; however it
was not possible to monitor the aerosol delivered to the
exposure chamber ports (point of administration (POA))
during exposures. Experimental analyses undertaken to
determine the link between the aerosol delivered to the
manifold and that delivered to each port (POA) indi-
cated that for all but the smallest aerosol particle size
the concentrations were approximately the same, but for
the smallest aerosol particle size (10 nm) losses occurred
resulting in the requirement for a correction factor of
0.72 ± 0.04 [9]. For the experiments using non-
radioactive iridium aerosols the system was modified to
allow particle size distribution measurements and sam-
pling for TEM to be carried out directly from a chamber
port, otherwise characterisation of the aerosol was
undertaken as indicated above.
Iridium electrodes
The iridium electrodes comprised 5 mm lengths of
0.8 mm diameter iridium wire (99.9% purity, Goodfellow
Cambridge Ltd, Huntingdon, UK). To produce radio-
active electrodes these were neutron activated at the
Imperial College Reactor Centre, Ascot, UK. The pri-
mary radionuclide produced is iridium-192, which has a
half-life of 74 days and decays principally by beta emis-
sion producing associated gamma rays of various ener-
gies [26]. The iridium-192 content of each electrode was
approximately 250 MBq at delivery.
Animals
All procedures involving the animals were performed in
accordance with the Animals (Scientific Procedures) Act
1986 as amended in 2012 (ASPA) which complies with
EU Directive 2010/63/EU, including review and approval
by the local Animal Welfare and Ethical Review Body.
The animals used were female rats (Wistar-Kyoto (WKY/
NHsd), Harlan, UK, supplied specific pathogen free). At
the time of exposure the animals were aged between 8
and 12 weeks, weighing between 130 and 180 g. The ani-
mals were maintained on a 12 h light/dark cycle within a
ScantainerTM ventilated cabinet (Scanbur, Karlslunde,
Denmark) in groups of 3 in polycarbonate cages, 1291H
Eurostandard Type III H (Tecniplast, Italy), meeting regu-
latory housing requirements (Code of Practice for the
Housing and Care of Animals Bred, Supplied or Used for
Scientific Purposes, Home Office (2014), as issued under
ASPA). Animals were welfare checked daily and food
(Type RMI, Special Diet Services, Witham, Essex, UK)
and municipal water were freely available at all times pre-
and post-exposure.
Directly following exposure to a radioactive iridium
aerosol the whole body iridium-192 content of all ani-
mals were measured (see section on radioactive sample
counting). The whole body iridium-192 content of live
rats was also measured at a number of times post-
exposure. Rats to be sacrificed at later times were re-
moved from their restraining tubes and maintained in
standard stock cages. The remaining rats were eutha-
nized immediately (i.e. within 15 mins) on completion of
the exposure. Animals were euthanized by lethal injec-
tion of pentobarbital sodium (450 mg/kg) administered
intraperitoneally. To minimise cross contamination dur-
ing dissection the dead animal was first secured in the
supine position on a clean dissection board and the
neck, chest and abdominal pelt then damped with a 70%
ethanol solution. Dissection equipment was frequently
exchanged for clean to avoid the spread of loose radio-
active material. The abdomen and thoracic cavity were
opened to expose the larynx, major veins were exposed
and a blood sample withdrawn using needle and syringe
(for a number of animals an alternative approach was
used in which a blood sample was taken from the lower
left hand heart ventricle), the trachea was tied off close
to the larynx, and then the peritoneal cavity opened and
the liver, kidneys and spleen removed. The lung, GIT,
head, head pelt and body pelt were also removed. For a
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number of animals brains were also removed. The or-
gans, tissues and remaining carcass were weighed, placed
in sample containers, and refrigerated prior to radio-
active counting. For a number of animals bronchoalveo-
lar lavage was undertaken prior to the removal of the
lung. A cannula was gently inserted and tied in place in
the trachea and chilled phosphate buffered saline (PBS)
was administered (10 × 10 mL) and aspirated slowly
through the needle hub. Each BALF sample was col-
lected separately, the iridium-192 content was measured
and then the sample was centrifuged at 500 xg for 5 min
at 4 °C to separate the cells from the supernatant. For a
number of animals the iridium-192 content of the cell
pellet and supernatant samples were measured. For a
number of animals BALF samples were then subject to
further cytotoxicological analysis (see below). A number
of BALF cell samples were fixed in 10% neutral-buffered
formalin for later imaging. A number of animals from
the main study were placed in metabolism cages at vari-
ous times post-exposure and faeces and urine collected
and refrigerated prior to radioactive counting.
Animals exposed to non-radioactive iridium aerosols
were sacrificed using the same procedure as above.
Bronchoalveolar lavage was performed on half of the an-
imals using the protocol indicated above. For the other
animals the lung was perfused slowly with approximately
200 mL of ice cold saline until the lung turned white.
Following vascular perfusion, the lungs were removed en
bloc and inflated and fixed with 2% gluteraldehyde in
buffer (0.1 M sodium cacodylate) at pH7.3, via the tra-
cheal cannula, at a pressure of 30 cm of water. For elec-
tron microscopy the left lung lobe was rinsed briefly in
buffer (0.1 M with respect to sodium cacodylate) at pH7.3
and 1 mm thick slices were cut from the central region
prior to processing for TEM imaging. Liver, kidneys, brain
and BALF cells were fixed by infusion with 10% neutral-
buffered formalin. For laser ablation ICP-MS and synchro-
tron X-ray spectroscopy analysis three consecutive 5 μm
sections were cut from the centre of each organ (lung
(diaphragmatic lobe), liver, brain and kidney).
Radioactive sample counting
The iridium-192 content of each sample was measured
using either a 1480 WizardTM 3” Automatic Gamma
Counter using MultiCalc software (Perkin Elmer, MA,
USA) for small samples (e.g. whole kidney, spleen, brain,
blood and daily excreta) or a Scintiflex 178 YP 254 NaI
“Well Counter” (Nuclear & Silica Products Ltd, High
Wycombe, UK) using Ortec Maestro software (ORTEC,
TN, USA) for larger samples (e.g. whole carcass, pelt).
The whole body content of live rats was determined
using the Well Counter. Animals were placed in expos-
ure tubes and inserted horizontally into the well counter
for up to 30 min. The iridium-192 content (Bq) of a
sample was determined by subtracting the background
count rate from the sample count rate for the detector
and dividing by the appropriate (i.e. counter and sample
type) detection efficiency. Sample activities were normal-
ised to the day of the exposure by correcting for radio-
active decay. Minimum detectable activity (MDA) levels
were calculated for each sample [27] and only values
above the MDA reported.
BALF cytotoxicity analysis
Cells from all the BALF were collected in 1 mL saline and
placed on ice. Cells were counted using a haemocytometer
under a microscope. Total BALF cell numbers were calcu-
lated and around 1 × 105 cells were precipitated onto
cytospin slides for cell population counting. Staining was
performed with Diff-QuickTM, following the manufac-
turer’s instructions. For each cytospin slide, at least 300
cells were counted to identify macrophages, neutrophils,
and lymphocytes according to standard morphology under
a microscope with x400 magnification.
Total protein, lactate dehydrogenase (LDH) and alka-
line phosphatase (ALP) assays were used to assess gen-
eral cytotoxicity using the supernatant of the first
bronchoalveolar lavage wash (samples were stored at
−80 °C before analysis). Assays were performed in 96-
well plates. For LDH assay (Promega), 50 μl of BALF
was added to 50 μl of reconstituted substrate solution
and incubated for 30 mins at room temperature in the
dark. Then 50 μl of stop solution was added to each well
and the absorbance (Ab) was measured at 492 nm. Total
protein was measured using Bio-Rad protein assay kit
and ALP was measured using Abcam alkaline phosphat-
ase assay kit.
Tissue sample imaging
Images of lung sections and BALF cells from animals
exposed to the non-radioactive 10 nm and 75 nm aerosols
were produced using a Zeiss 902A electron microscope.
Following this initial analysis, further images of some of
the particles found in the BALF cells were produced using
a JEOL 2010 analytical transmission electron microscope
with a resolution of 0.19 nm and electron probe size down
to 0.5 nm. This instrument was equipped with an Oxford
Instruments LZ5 windowless energy dispersive X-ray
spectrometer (EDS) to enable elemental analysis.
Laser ablation inductively coupled plasma mass spec-
trometry (LA-ICP-MS) analyses of lung, liver, kidney
and brain sections and BALF cells mounted on micro-
scope slides were undertaken using a New Wave Re-
search NWR213 laser ablation system (Electro Scientific
Industries, Portland, Oregon, USA) linked to a iCAP Q
ICP-MS (Thermo Fisher Scientific, Hemel Hempstead,
UK). Unless otherwise stated, laser ablation conditions
comprised 100 μm diameter spot size, fluence 7 J/cm2,
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400 μms−1 scan speed and a repetition rate of 20Hz. The
cell gas was helium which was run at a flow of 0.9
mLmin−1. Helium was also used as the collision gas in
KED mode. Samples were introduced into the ICP-MS
via a micro flow nebuliser. The ICP-MS was run in KED
mode and the isotopes monitored were carbon-13,
copper-63, zinc-66 and iridium-193. Dwell time for each
isotope was 0.05 s. Scan log files were generated to allow
reconstruction of the data into an image. Image gener-
ation was achieved using Iolite v3 [28] within Igor Pro
6.36 (Wavemetrics Inc. Oregon, USA). Basically, the
scan log file was aligned with the ICP-MS data exported
from Qtegra as an excel.csv file, to identify data of inter-
est. Baseline values were then subtracted using the data
reduction scheme using carbon-13 as the index channel.
Synchrotron micro focus x-ray fluorescence (μ-XRF)
was used to produce elemental maps of lung sections
and BALF cells. For identified areas of high iridium
concentration micro focus X-ray near-edge absorption
spectroscopy (μ-XANES) was used to explore iridium
speciation via comparison with spectra produced for a
range of reference samples, including iridium wire, irid-
ium nanoparticles sampled from the aerosol onto a filter,
iridium oxide (Sigma Aldrich, Gillingham, UK), iridium
chloride (Fisher Scientific, Loughborough, UK), and irid-
ium dodecacarbonyl (Sigma Aldrich, Gillingham, UK). This
was undertaken using the microfocus spectroscopy beam-
line, I18 [29], at the Diamond Light Source. The μ-XRF
mapping of iridium and other elements was undertaken
using a beam focus of circa 4 × 4 μm. The iridium L(III)-
edge spectra was used for the μ-XANES analysis with a
step size of 5 eV for the majority of the spectra reducing to
0.5 eV where more detailed resolution was required.
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